Granules India Q3FY26 Revenue Jumps 22% YoY to ₹13,879 Million, PAT up 28%
Granules India reported Q3FY26 revenue of ₹13,879 million, up 22% YoY. EBITDA rose 34% to ₹3,081 million and PAT increased 28% to ₹1,502 million. The growth was driven by the Finished Dosages segment. ROCE stood at 16.8% and Net debt to EBITDA was 0.91x.
Significant year-on-year growth in revenue and profits, driven by strategic segments and positive management commentary, is likely to have a high impact on investor sentiment and the company's stock.
The company reported strong year-on-year growth across key financial metrics like revenue, EBITDA, and PAT, indicating a positive financial performance.
Granules India Limited announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a significant year-on-year growth, with revenue from operations reaching ₹13,879 million (up 22% YoY), driven primarily by the Finished Dosages (FD) segment in North America and Europe.
EBITDA for the quarter stood at ₹3,081 million, a 34% increase YoY, while Profit Before Tax (PBT) grew by 32% YoY to ₹2,022 million. Profit After Tax (PAT) saw a 28% YoY increase, reaching ₹1,502 million. The EBITDA margin was 22% and PAT margin was 11% for Q3FY26.
The company's diverse business segments contributed to this performance, with Finished Dosages (FD) accounting for 76% of revenue, followed by Active Pharmaceutical Ingredients (API) at 11%, Pharmaceutical Formulation Intermediates (PFI) at 11%, and Peptides/CDMO at 2%. Return on Capital Employed (ROCE) was reported at 16.8% post the acquisition of Senn Chemicals AG.
Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, stated, "Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders."
As of December 31, 2025, the net debt was ₹10,151 million, with a Net debt to EBITDA ratio of 0.91x.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.